Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of March 2020. The report details the departure and appointment of the Chief Financial Officer and provides the results of the Annual Meeting of Shareholders held on March 10, 2020, for the fiscal year ending March 31, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Leadership Change: On March 8, 2020, Mr. Yao (Alex) Shi resigned as Chief Financial Officer (CFO). Mr. Peter Chan was appointed as the new CFO effective immediately.
- Shareholder Voting Results:
- Directors Elected: Feng Zhou, Jun Zheng, Junsong Li, Tulin Lu, and Wenwei Fan were elected to the Board of Directors.
- Accounting Firm: Shareholders ratified Centurion ZH CPA, LLC as the independent registered public accounting firm.
- Executive Compensation: Shareholders approved the executive compensation proposal and voted to hold advisory votes on this matter every three years.
- Charter Amendment: Shareholders approved an amendment to the Memorandum and Articles of Association, granting the Board authority to amend authorized share capital, divide or combine shares, and change meeting quorum requirements to one-third of voting rights.
Guidance, Outlook, and Risks
The filing includes a standard Special Note Regarding Forward-Looking Statements, cautioning that actual results may differ materially from expectations due to risks and uncertainties. Management commentary highlights that the new CFO, Mr. Peter Chan, brings over twenty years of experience in funding, mergers, and acquisitions, which is expected to be critical for the Company's future business expansion. No specific financial guidance or numerical outlook was provided in this document.
Investor Verification Checklist
- Verify the background and qualifications of the new CFO, Mr. Peter Chan, as detailed in the attached employment agreement (Exhibit 99.1).
- Review the specific terms of the Charter Amendment regarding the Board's new authority over share capital and quorum requirements.
- Confirm the quorum and voting percentages for the Annual Meeting (58.86% of outstanding shares represented).
- Check subsequent filings for the first financial report under the new CFO's tenure.